Xeris Biopharma Holdings, Inc. XERS Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Corcept TherapeuticsCORT

$9.42M+42.6%

Eton Pharmaceuticals, Inc.ETON

$515K+214%

Zevra Therapeutics, Inc.ZVRA

$1.5M-5.6%

Crinetics PharmaceuticalsCRNX

$47.86M-5.8%

Neurocrine BiosciencesNBIX

$463.5M-6.0%

Arrowhead ResearchARWR

$107.88M-5.6%

FAQ

What is Xeris Biopharma Holdings, Inc.'s operating lease liabilities (total)?

Xeris Biopharma Holdings, Inc. (XERS) reported operating lease liabilities (total) of $36.85M in Q2 2026.

How has Xeris Biopharma Holdings, Inc.'s operating lease liabilities (total) changed year-over-year?

Xeris Biopharma Holdings, Inc.'s operating lease liabilities (total) decreased by 4.5% year-over-year, from $38.6M to $36.85M.

What is the long-term trend for Xeris Biopharma Holdings, Inc.'s operating lease liabilities (total)?

Over 3 years (2022 to 2025), Xeris Biopharma Holdings, Inc.'s operating lease liabilities (total) has grown at a 50.9% compound annual growth rate (CAGR), from $10.98M to $37.76M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.